Related Experiment Video
Updated: Jun 18, 2026
Revealing the Ferroptotic Phenotype of Medulloblastoma
Published on: March 15, 2024
STXBP1 inhibits glioma progression by modulating ferroptosis and epithelial-mesenchymal transition
Xuemin Li1, Chonggong Zhang2, Peiyu Qian3
1Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Caoyang, Putuo District, Shanghai, China.
Introduction:
This study investigated the role of STXBP1 in glioma, particularly its involvement in regulating ferroptosis and epithelial-mesenchymal transition (EMT), and examined its impact on glioma cell behavior.
Material And Methods:
Differential gene expression analysis was performed on a glioma dataset, and protein-protein interaction (PPI) network analysis identified genes with significant prognostic value. Least absolute shrinkage and selection operator (LASSO) Cox regression analysis further narrowed the scope. Key genes were obtained through nomogram analysis, and expression verification was performed. In in vitro cell experiments, knockdown of STXBP1 was performed in glioma cell lines. The effects on cell proliferation, migration, invasion, cell cycle distribution, apoptosis, and markers of ferroptosis and EMT were assessed.
Results:
After bioinformatics analysis, STXBP1 was identified as a hub gene, and in vitro cell experiments were performed. STXBP1 knockdown in glioma cells increased proliferation, migration, and invasion, altered cell cycle distribution (reducing S phase and increasing G1 phase), and decreased apoptosis. Ferroptosis markers showed elevated GPX4 expression and reduced 12-HETE and 15-HETE levels. Ferroptosis inducers (sorafenib, erastin) heightened LDH release and reduced viability, while inhibitors (ferrostatin-1, U0126) had opposing effects. STXBP1 knockdown also reduced lipid peroxidation and mitigated the cytotoxic effects of sorafenib, indicating a role in ferroptosis regulation. Additionally, STXBP1 knockdown impacted EMT markers, decreasing N-cadherin and vimentin and increasing E-cadherin.
Conclusions:
STXBP1 functions as a tumor suppressor in glioma, regulating ferroptosis and EMT. It shows potential as a therapeutic target in glioma management.
Insights
STXBP1 acts as a tumor suppressor in glioma by regulating ferroptosis and epithelial-mesenchymal transition (EMT). Downregulating STXBP1 promotes glioma cell growth and impacts key ferroptosis and EMT markers, suggesting therapeutic potential.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Glioma is a complex brain tumor with limited treatment options.
- Understanding novel molecular mechanisms is crucial for developing targeted therapies.
- STXBP1's role in glioma, particularly in ferroptosis and EMT, remains largely unexplored.
Purpose of the Study:
- To investigate the function of STXBP1 in glioma.
- To determine STXBP1's involvement in regulating ferroptosis and epithelial-mesenchymal transition (EMT).
- To assess the impact of STXBP1 on glioma cell behavior and its potential as a therapeutic target.
Main Methods:
- Bioinformatic analysis including differential gene expression, protein-protein interaction (PPI) network, LASSO Cox regression, and nomogram analysis.
- In vitro experiments involving STXBP1 knockdown in glioma cell lines.
- Assessment of cell proliferation, migration, invasion, cell cycle, apoptosis, ferroptosis markers (GPX4, 12-HETE, 15-HETE, LDH, lipid peroxidation), and EMT markers (E-cadherin, N-cadherin, vimentin).
Main Results:
- STXBP1 was identified as a key hub gene in glioma.
- STXBP1 knockdown significantly increased glioma cell proliferation, migration, and invasion.
- STXBP1 knockdown altered cell cycle distribution, decreased apoptosis, modulated ferroptosis markers, and reversed EMT phenotypes.
Conclusions:
- STXBP1 functions as a tumor suppressor in glioma.
- STXBP1 plays a critical role in regulating ferroptosis and EMT in glioma cells.
- STXBP1 represents a potential therapeutic target for glioma treatment.